Post-marketing safety evaluation of S-1 in patients with inoperable or recurrent breast cancer: Especially in patients treated with S-1 + trastuzumab

Japanese Journal of Clinical Oncology

Volumn 41, Issue 9, 2011, Pages 1051-1058

  Saito, Yuki ^a   Oshitanai, Risa ^a   Terao, Mayako ^a   Terada, Mizuho ^a   Tsuda, Banri ^a   Okamura, Takuho ^a   Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Post marketing surveillance; S 1; Trastuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; TRASTUZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST CANCER; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE COUNT; HAND FOOT SYNDROME; HUMAN; JAPAN; LEUKOCYTE COUNT; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALAISE; MONOTHERAPY; NAUSEA; NEUTROPHIL COUNT; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; JAPAN; LOGISTIC MODELS; MIDDLE AGED; OXONIC ACID; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TEGAFUR;

EID: 80052475998     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr099     Document Type: Article

References (12)

1. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993;53:4004-9.
2. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
3. Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, et al. A phase II study of S-1 in patients with metastatic breast cancer, a Japanese trial by the S-1 Cooperative Study Group (Breast Cancer Working Group). Breast Cancer 2004;11:194-202.
4. Hino M, Saeki T, Sato Y, Sano M, S-1 Cooperative Study Group (Breast Cancer Working Group). Late phase II study of S-1 in patients with taxane resistant breast cancer. J Clin Oncol 2004;22(14S):745 (ASCO Annual Meeting Proceedings).
5. NCCN Clinical Practice Guidelines in Oncology™. Breast Cancer. 2010; NCCNw Practice Guidelines in Oncology. Version 2.
6. Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 2008;61:509-14.
7. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer 2007;10:129-34.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
9. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
10. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-8.
11. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;15:2722-30.
12. Yasuhiro S, Yuki S, Takuho O, Banri T, Mayako T, Mizuho T, et al. Study of S-1/trastuzumab combination therapy for HER2-positive metastatic breast cancer. Global Breast Cancer Conference, 2009 (PO1-033).